Nomenclature of the contact factors
Factor XI and the Contact System

Person responsible (Chair / Principal Investigator): Joost Meijers / Alvin Schmaier

Description Abstract

State the application’s broad, long-term objectives and specific aims, making reference to the health relatedness of the project. Suggested length is 2-3 paragraphs.

The abbreviations of the nomenclature of the contact factors (factor XI, prekallikrein, high molecular weight kininogen and factor XII) are not firmly established. In the literature many variations are used for the abbreviation of these proteins. Although, this field is undergoing a number of changes with the recognition of novels forms of these proteins, our subcommittee would like to propose a consensus definition of the abbreviations for the zymogen proteins, their enzymatic forms, and the field’s cofactor and its activated form.

Design and methodology (Data expected to collect, sample size and statistical analysis):

Describe concisely the research design and methods for achieving these goals. Suggested length 2-3 paragraphs

Annually at our SSC subcommittee sessions since Montpellier (2016), Alvin Schmaier chaired a working group consisting of Drs. Joost Meijers, Coen Maas, David Gailani, James Morrissey, Thomas Renne, Allen Kaplan, Jose Govers-Riemslag, Jonas Emsley, Edward Feener and Johannes Sidelmann. This group at the Berlin SCC (2017) meeting and by email (January 2018) discussed the currently used wide variety of names and abbreviations of the contact system proteins. A consensus list of names and abbreviations based upon these discussions have been compiled by Alvin Schmaier. This list will be presented and explained during our SCC subcommittee session in Dublin 2018. After the presentation, we will ask the group if we can have a vote by a show of hands to adopt the list as a whole or in part. The agreed upon procedure will then be brought to the floor for a vote by a show of hands. The result will be compiled into a report for publication as an SSC communication early 2019.

Study population (Inclusion, exclusion, eligibility) (patient population; recruitment of participating institutions/physicians and subjects; minimum number needed; expected number):

Suggested length 2-3 paragraphs

Not applicable.
Expected timeline:

- Project stage/set up
- Launch
- Duration
- Finalization/analysis
- Reporting

*See Design and methodology.*

Expected outcomes (ie. publications):

Publication type (SSC Communication, Guidance document or original article):

*The consensus of the names of the proteins and agreed upon abbreviations for zymogens, enzymes, or intact or activated cofactor of the contact system will be assembled into an SCC communication for investigators in the field.*

*SSC Communication.*

Description of project set/up and management, needed infrastructure and resources (summary):

*No resources needed.*

Possible references: